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 6 50 (497 AU; p = 0.031). Concerning the infarction vol-
ume, nucleosomes showed signifi cant correlations for 
the concentrations on day 3 (r = 0.43; p = 0.001) and for 
the area under the curve (r = 0.34; p = 0.016).  Conclusion: 
Even if nucleosomes are nonspecifi c cell death markers, 
their release into serum after cerebral stroke correlates 
with the gross functional status as well as with the infarc-
tion volume and can be considered as biochemical cor-
relative to the severity of stroke. 
 Copyright © 2006 S. Karger AG, Basel 
 Introduction 
 During cerebral ischemia, hypoperfusion leads to cell 
death by excitotoxicity, permanent or partially depolar-
ization, Ca 2+  overload and free radicals, particularly in 
the ischemic core  [1–3] . In contrast, cellular energy mech-
anisms are partially conserved in the penumbra. In case 
of continuously insuffi cient blood supply, delayed apop-
totic cell death may result in a considerably larger infarc-
tion volume. The extent of cellular demise might be ef-
fective for the outcome of patients after long-term recov-
ering processes  [1] . As the blood-brain barrier is often 
disrupted after stroke, the products released by degraded 
cells gain access to the circulation and can be measured 
in serum and plasma. 
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 Abstract 
 Background: Nucleosomes are cell death products that 
are elevated in serum of patients with diseases that are 
associated with massive cell destruction. We investigat-
ed the kinetics of circulating nucleosomes after cerebral 
stroke and their correlation with the clinical status.  Meth-
ods: In total, we analyzed nucleosomes by ELISA in sera 
of 63 patients with early stroke daily during the fi rst week 
after onset. For correlation with the clinical pathology, 
patients were grouped into those with medium to slight 
functional impairment (Barthel Index BI  6 50) and those 
with severe functional impairment (BI  ! 50).  Results: Pa-
tients with BI  6 50 showed a continuous increase in nu-
cleosomes until day 5 (median: 523 arbitrary units, AU) 
followed by a slow decline. In contrast, patients with BI 
 ! 50 showed a steeper initial increase reaching a maxi-
mum already on day 3 (869 AU). Both, days after stroke 
(p  ! 0.001) and BI (p  ! 0.001), had a signifi cant infl uence 
on nucleosome concentrations, respectively. Consis-
tently, patients with BI  ! 50 had a signifi cantly larger area 
under the curve (AUC/day) of nucleosome values during 
the fi rst week after stroke (800 AU) than patients with BI 
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 Essential products of apoptosis are circulating nucleo-
somal DNA fragments. They are basic elements of chro-
matin and consist of a compound of histone core proteins 
and DNA on the outside. During apoptosis, several en-
donucleases cleave the chromatin at the easily accessible 
internucleosomal linking sites specifi cally into mono- 
and oligonucleosomal fragments that are released into 
the circulation after degradation of the cellular mem-
brane  [4, 5] . 
 Nowadays it is known that the rate of apoptosis and 
consequently the  release of DNA are increased during 
various acute and chronic diseases, such as cancer  [6, 7] , 
during graft rejection  [8] , trauma  [9] , stroke  [10] and also 
during pregnancy  [11] . Many of these studies were carried 
out using real-time PCR for DNA quantifi cation. Using 
this method, proteins are separated from DNA before 
measurement of DNA concentration. However, as the as-
sociation of DNA with proteins preserves them from fur-
ther digestion in serum, most of the extracellular DNA is 
thought to be present in the form of nucleosomes  [4] . 
 In patients with stroke, a recent study has shown that 
DNA levels in the early ischemic phase possess prognos-
tic value for the 28-day and 6-month mortality  [10] . Due 
to the one-time investigation, it was not clear whether the 
initial DNA level or later time points would be most ef-
fective due to the dynamic development of stroke and its 
interindividual heterogeneity. Therefore we measured 
the course of nucleosomal DNA in the blood of patients 
with cerebral ischemia in a closely monitored manner 
during the fi rst week after onset of the symptoms. These 
results were correlated in a fi rst step with the clinical sta-
tus of the patients objectifi ed by the Barthel Index (BI) 
 [12] and the infarction volume to elucidate whether non-
specifi c biomarkers of cell death are associated with the 
severity of stroke. 
 Patients and Methods 
 Patients 
 In total, we investigated serum samples of 63 patients with ce-
rebral ischemic stroke. The localization of the occlusion was in 50 
patients the middle cerebral artery, in 3 the posterior cerebral artery, 
in 2 infarctions of the thalamus, in 2 the posterior inferior cerebellar 
artery and in 6 an artery of the brainstem ( table 1 ). All patients were 
admitted to the Stroke Unit at the University Hospital Munich-
Grosshadern where they received standard stroke care. 
 In our study, we included all patients with stroke symptoms 
which occurred within a time frame of maximally 24 h before hos-
pitalization and a BI  [11] available at admission. Exclusion criteria 
were neoplasms, chronic infl ammatory diseases and cytostatic ther-
apy at the time of stroke, hemoglobin  ! 9 mg/dl and stroke-specifi c 
symptoms that had started earlier than 24 h before admission. The 
study was approved by the local ethics committee. Informed writ-
ten consent was obtained either from the patient or a relative in all 
cases. 
 The functional impairment at admission was objectifi ed by the 
BI  [11] indicating the everyday ability of self-supply (range: 0–100 
points). For our evaluation, patients were grouped according to the 
median into those with only slight to moderate functional impair-
ment (BI  6 50; n = 31) and those suffering from severe functional 
impairment (BI  ! 50; n = 32). 
 Methods 
 Nucleosomes were measured in serum at the time of hospital-
ization and at least once daily during the fi rst week. Because of 
nucleosome instability, a strict preanalytical protocol was followed. 
Blood samples were centrifuged within 1–2 h after blood drawing. 
Subsequently, 10 m M EDTA were added and the samples were 
stored at –70  °  C. Quantifi cation of nucleosomes was performed us-
ing the Cell Death Detection ELISA Plus  (Roche Diagnostics, Ger-
many) which is based on a quantitative sandwich enzyme immu-
noassay principle. Samples were placed into a microtiter plate, and 
Table 1. Patient characteristics
Median age, years
Range
67.9 
32–88
Gender Male 36
Female 27
Stroke localization Middle cerebral artery 50
Posterior cerebral artery 3
Thalamus 2
Posterior cerebellar artery 2
Brainstem 6
Etiology Cardioembolic 27
Arterioembolic 23
Microangiopathic 6
Traumatic dissection 4
Unknown 3
Risk factors Arterial hypertension 45
Hypercholesterolemia 22
Diabetes mellitus 14
Nicotine abuse 19
Coronary heart disease 11
BI 75–100 17
50–<75 14
40–<50 2
30–<40 3
20–<30 7
10–<20 4
0–<10 16
Infarction volume 0–<25 cm3 30
25–<50 cm3 8
50–<100 cm3 6
100–<200 cm3 3
>200 cm3 2
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a buffer solution was added containing two monoclonal antibodies 
which are directed against DNA and histones (from the mouse 
clones M-CA-33 and H11-4), respectively, for the specifi c detection 
of mono- and oligonucleosomes. The antihistone antibodies were 
biotinylated and fi xed the complexes to the microtiter plate where-
as the anti-DNA antibodies were associated with a peroxidase label 
that reacts with the substrate 2,2  -azino-di-3-ethylbenzthiazoline 
sulfonate. The resulting color development, which is proportional 
to the concentration of the nucleosomes captured by the antibody 
sandwich, was measured photometrically at 405 nm. For measure-
ment of nucleosomes in serum, a standard curve was established 
using plasma of several healthy donors which was stimulated to 
induce apoptosis by a mixed lymphocyte reaction as specifi ed in 
Holdenrieder et al.  [7] . Nucleosomes were quantifi ed in relative 
arbitrary units (AU). Blood samples from each patient were mea-
sured within the same run to improve the comparability of the re-
sults. Details of the preanalytical sample handling are described in 
Holdenrieder et al.  [7] . 
 The extent of the morphological damage was determined in the 
fi rst hours after admission to the hospital by computed tomography 
(CT) and/or during the fi rst days by diffusion-weighted magnetic 
resonance imaging (MRI), which is highly sensitive to early cerebral 
stroke  [13] . In our evaluation we considered only the fi rst CT or 
MRI scan as the fi rst days were the most homogenous time points 
with cerebral images available. The analysis of volume measure-
ments was performed by an experienced radiologist for the MRI 
imaging on a Linux working station using MedX 3.4.1 software (by 
Sensor Systems, www.sensor.com); for patients who were imaged 
by CT, the quantifi cation was performed on the PACS station 
(Magic View B1, Siemens Medical Systems, Forchheim, Germany). 
In every instance, the ischemic region was manually outlined on 
each image slice: the area of the outlined region was multiplied by 
the thickness for either CT or MR images, plus the interslice gap 
for MR images (of 0.25), and then summed to give the total lesion 
volume. 
 Statistics 
 For statistical analysis, various variables of nucleosomes were 
considered, such as the absolute concentrations determined at ad-
mission and daily during the fi rst week after stroke, and the area 
under the curve (AUC/day) that integrated all values of the fi rst 
week after onset of stroke. For calculation of this variable, at least 
the nucleosome values of day 1, of days 3 or 4 and of days 5–7 were 
mandatory. Due to variabilities in the term of hospitalization, the 
area was normalized by division of the number of days. 55 patients 
fulfi lled the criteria for calculation of the AUC. 
 Infl uence of day after stroke and BI (BI  6 50 vs. BI  ! 50) on nu-
cleosome concentration was tested simultaneously by two-way 
Anova using ranks of data. Discriminating power of the AUC/day 
of nucleosome levels between patients with slight functional im-
pairment (BI  6 50) and those with heavy functional impairment 
(BI  ! 50) was analyzed by the Wilcoxon test. Continuous correla-
tions of nucleosomes and infarction volume as well as of infarction 
volume and BI were calculated by Spearman’s rank correlation to-
gether with the 95% confi dence interval. A p value  ! 0.05 was con-
sidered statistically signifi cant. All p values are two-sided. Statisti-
cal analyses were performed with software of SAS (version 8.2, SAS 
Institute Inc., Cary, N.C., USA). 
 Results 
 Generally, we observed during the fi rst days after onset 
of stroke a considerable increase in the concentration of 
nucleosomes in serum reaching a maximum after 2–5 
days. Afterwards the values decreased again slowly. In 
patients with BI  ! 50, the increase started already shortly 
after the ischemic event (medians: day 1, 145 AU; day 2, 
524 AU) and reached the maximum after 3 days (869 AU) 
which was subsequently followed by a decline until day 7 
(591 AU). In patients with BI  6 50, the values increased 
more slightly (day 1: 125 AU, day 2: 288 AU) reaching 
the maximum on day 5 (523 AU) followed by a decrease 
until day 7 (338 AU). When testing simultaneously the 
infl uence of days after stroke and BI on nucleosome con-
centrations by two-way Anova, highly signifi cant results 
were obtained for both days after stroke (p  ! 0.001) and 
BI (p  ! 0.001). Correspondingly, patients with BI  ! 50 had 
a signifi cantly larger AUC/day of nucleosome values dur-
ing the fi rst week after stroke (800 AU) than patients with 
BI  6 50 (497 AU; p = 0.031). 
 Figure 1 shows typical kinetics of nucleosomes in 2 
patients, one with a slight functional impairment ( fi g. 1 a: 
BI = 100) and one with a severe functional impairment 
( fi g.  1 b: BI = 20): the fi rst exhibited only a fl at course re-
sulting in a small AUC, whereas the latter had a consider-
able increase in nucleosome concentrations resulting in a 
larger AUC ( fi g. 1 ). In  fi gure 2 , nucleosome concentra-
tions of all patients are expressed as median, quartiles and 
ranges for every day during the fi rst week after stroke, and 
for the AUC showing considerable differences in nucleo-
some levels between patients with slight (BI  6 50) and 
those with severe functional impairment (BI  ! 50;  fi g. 2 ). 
 Concerning the infarction volume, nucleosome con-
centrations showed signifi cant correlations for day 3 (r = 
0.43; p = 0.001) and for the AUC (r = 0.34; p = 0.016) 
( table 2 ,  fi g. 3 ). In addition, the infarction volume corre-
lated inversely with the BI at admission (r = –0.56;
p  ! 0.0001). 
 Discussion 
 Cerebral hypoperfusion leads to various pathological 
features which are caused by excitotoxicity, peri-infarct 
depolarization, infl ammation and cell death. Concerning 
the mode of cell death, necrosis might predominantly oc-
cur in the ischemic core where cells are damaged most 
severely and irreversibly. In contrast, apoptosis might be 
mainly present in the penumbra where cellular mecha-
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nisms are impaired by the restricted blood supply  [1] . 
Presumably, cells are fi rst arrested in their cycles to initi-
ate repair and rescuing systems. Only if they fail, cells will 
decay after a certain time delay. In addition, some studies 
report that apoptotic and necrotic features may occur in 
the same cells at various time levels depending on the 
properties and demands of the cells, and they suggest the 
term ‘aponecrosis’  [14] . 
 Biochemical markers refl ect the pathophysiological 
processes and are potentially helpful for the diagnosis, 
monitoring and prognosis of stroke. Among the serum 
parameters that have shown to be released after stroke are 
more unspecifi c markers like glucose  [15, 16] and C-reac-
tive protein  [17, 18] , and specifi c markers for neuronal 
degradation and glia activation like neuron-specifi c eno-
lase and S100 protein  [19, 20] . 
 Nucleosomal DNA fragments have been described as 
typical cell death products that are released particularly 
during apoptosis. However, elevated levels of nucleosomes 
have also been observed during acute infl ammations and 
during various malignant processes  [6] . Therefore it is 
hardly likely that nucleosomes might be valuable for the 
 Fig. 2. Nucleosome concentrations (AU; 
median, quartiles and ranges) during the 
fi rst week after cerebral infarction in pa-
tients with slight (BI  6 50) and those with 
severe functional impairment (BI  ! 50). Si-
multaneous two-way Anova testing re-
vealed a signifi cant infl uence of days after 
stroke (p  ! 0.001) and BI (p  ! 0.001) on nu-
cleosome concentrations. 
 Fig. 1. Courses of nucleosome concentra-
tions during the fi rst week after cerebral 
stroke in a patient with infarction of the 
middle cerebral artery and a BI of 100 
points at admission ( a ) and in a patient with 
infarction of the middle cerebral artery and 
a BI of only 20 points ( b ). 
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diagnosis of any specifi c disease or of stroke. Most impres-
sively, a recent study on circulating DNA determined at 
early stages of stroke has shown a close association with 
survival of stroke patients: Rainer et al.  [10] reported on 
88 stroke patients whose high DNA levels were signifi cant-
ly correlated with an increased mortality rate within 28 
days as well as within 6 months after stroke. They found 
this parameter having a specifi city of 74.4% and a sensitiv-
ity of 100% for the prediction of hospital mortality  [10] . 
These results are all the more interesting as stroke is known 
to be a dynamic process with considerable interindividual 
heterogeneity in its development and manifestation. 
 Based on these results we conducted a study with se-
rial determinations of nucleosomal DNA fragments in 
blood to see (a) whether there exist typical kinetic patterns 
of DNA release after stroke, (b) whether they are related 
to the clinical status of stroke patients and (c) whether 
they are related to the infarction volume. 
 For the measurement of nucleosomes we used an ELI-
SA that has been developed recently and has shown a 
good methodological performance  [5] . It detects specifi -
cally the nucleosomal complexes of histones and DNA in 
the blood. Even if Rainer et al.  [10] quantifi ed DNA by 
a PCR technique which includes the separation of DNA 
from histone proteins by proteinase K digestion, the re-
sults should be comparable as it is known that most of the 
circulating DNA in blood occurs in the form of nucleo-
somes and only a small amount as free DNA  [21, 22] . 
 Our results showed heterogeneous kinetic patterns of 
DNA release into serum after stroke. However, we ob-
served in most patients an increase during the fi rst days 
after onset of the symptoms reaching the maximum on days 
3–5. These fi ndings are in accordance with the kinetics of 
apoptosis induction that is known to be strongest after 48–
72 h after severe cell damage  [23] . However, infl ammatory 
processes might contribute to the elevation of nucleosome 
values at that time, too. When dividing the patients accord-
ing to the severity of the functional impairment into those 
with BI  ! 50 and BI  6 50, the initial nucleosome concen-
trations did not show signifi cant differences between both 
groups. In the further follow-up of patients with severe 
functional impairments, the nucleosome levels increased 
earlier and more strongly than in those having only slight 
to moderate functional lesions. Consistently, the area un-
der the curve of nucleosome values during the fi rst week 
after stroke differed signifi cantly between both groups. For 
the concentrations on day 3 and the AUC, we also found a 
signifi cant correlation with the infarction volume. 
 Our results indicate that nucleosomal DNA as typical 
cell death marker is released in a time- and severity-depen-
dent manner after stroke which can also be followed in 
serum. Whether the increase in nucleosomal amount in 
blood after several days is only the result of the initial cell 
damage or whether it mainly refl ects further pathophysi-
ological processes that are still taking place days after the 
onset of stroke remains to be clarifi ed. The individual dy-
namics of stroke development was not mapped by imaging 
techniques either as they were only performed at the initial 
Table 2. Correlation of nucleosome concen-
trations during the fi rst week after stroke 
and infarction volume (Spearman rank cor-
relation)
Correlation 
coeffi cient
p
value
Day 1 0.14 0.433
Day 2 0.02 0.875
Day 3 0.43 0.001
Day 4 0.25 0.068
Day 5 0.26 0.081
Day 6 0.21 0.178
Day 7 0.19 0.288
AUC/day 0.34 0.016
 Fig. 3. Correlation of nucleosome concentration on day 3 after 
stroke with infarction volume (r = 0.43; confi dence interval 0.21–
0.65; p = 0.001; Spearman rank correlation). 
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phase of stroke. This might have led to an underestimation 
of the stroke volume particularly in those cases where the 
dimension of the infarction increased later on. 
 Concerning the source of circulating nucleosomal 
DNA, several hypotheses might be taken into account: 
First, they could derive from cell death within the injured 
brain. As nucleosomes correlate with infarction volume 
and clinical status of the patients, this explanation sounds 
reasonable; however, it is not necessarily deductable. Al-
ternatively they might be released by apoptotic infl am-
matory cells like polymorphonuclear leukocytes or lym-
phocytes which are known to migrate into the cerebral 
circulation and infi ltrate the injured area  [1] . As the se-
verity of the ischemic event may be related to the quan-
tity of infi ltrating leukocytes, circulating nucleosomal 
DNA could also simply refl ect the extent of leukocyte 
apoptosis. Finally, as leukocyte activation is also seen in 
the periphery after stroke, they could at least contribute 
to the release of circulating DNA. Performing correla-
tions of nucleosomal DNA with leukocytes and C-reac-
tive protein as infl ammatory parameters as well as with 
neuron-specifi c enolase and S100 protein as markers of 
neuronal degradation and glia activation might be appro-
priate to address these hypotheses. 
 Nevertheless, the correlation of the kinetics of circu-
lating nucleosomal DNA in serum with the extent of 
 functional lesions and one-time determination of the in-
farction volume might be valuable for upcoming investi-
gations on the heterogeneous development and manifes-
tation of stroke as well as potentially for the individual 
monitoring of stroke in future. Besides the comparison 
with more specifi c markers like neuron-specifi c enolase 
and S100 protein, the next essential steps in the evalua-
tion of the power of nucleosomes in stroke patients will 
include the prognostic analysis to distinguish different 
stroke populations, etiologies and treatment effects. 
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